Evolution in treatment of ST-segment elevation myocardial infarction

Authors: Efendieva A.S., Bulaeva N.I., Golukhova E.Z.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Reviews

DOI: https://doi.org/10.24022/1997-3187-2023-17-2-203-216

For citation: Efendieva A.S., Bulaeva N.I., Golukhova E.Z. Evolution in treatment of ST-segment elevation myocardial infarction. Creative Cardiology. 2023; 17 (2): 203–16 (in Russ.). DOI: 10.24022/1997-3187-2023-17-2-203-216

Received / Accepted:  03.04.2023 / 27.06.2023

Keywords: acute myocardial infarction ischemic heart disease percutaneous coronary intervention antiplatelet therapy

Subscribe 🔒



Coronary heart disease (CHD) occupies a leading position among all causes of death, while the maximum mortality is observed in myocardial infarction (MI) with the ST-segment elevation. Understanding the pathophysiology of MI revolutionized the approach to treatment with the consistent use of thrombolytic therapy, the development of optimal antiplatelet therapy, surgical coronary revascularization and percutaneous coronary intervention (PCI) with primary coronary angioplasty and intracoronary stent placement. It became clear that the timing of revascularization plays a key role and influence on the favorable outcome, and a clear relationship was traced between the time of ischemia and the size of myocardial infarction. As the result there was established the principle of the “golden hour”, which was later confirmed by multiple randomized trials. With the implementation of the recommendations and strict observance of all time intervals, the effectiveness of medical care for patients with acute MI in recent years has exceeded 80%.


  1. Kudryashova E.N., Berdibekov B.Sh., Bulaeva N.I., Golukhova E.Z. The choice of revascularization method in patients with stable coronary artery disease and diabetes mellitus. Creative Cardiology. 2021; 15 (1): 61–71 (in Russ.). DOI: 10.24022/1997-3187-2021-15-1-61-71
  2. Smilowitz N.R., Feit F. The History of primary angioplasty and stenting for acute myocardial infarction. Curr. Cardiol. Rep. 2016; 18: 1–11. DOI: 10.1007/s11886-015-0681-x
  3. Herrick J.B. Landmark article (JAMA 1912). Clinical features of sudden obstruction of the coronary arteries. JAMA. 1983; 250 (13): 1757–62. DOI: 10.1001/jama.250.13.1757
  4. Tillett W.S., Garner R.L. The fibrinolytic activity of hemolytic streptococci. J. Exp. Med. 1933; 58 (4): 485–502. DOI: 10.1084/jem.58.4.485
  5. Fletcher A.P., Alkjaersig N., Smyrniotis F.E. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans. Assoc. Am. Physicians. 1958; 71: 287–96.
  6. Chazov E.I., Andreenko G.V. The first experience of thrombosis therapy with domestic fibrinolysin. Kardiologiya. 1962; 4: 59–63 (in Russ.)
  7. Chazov E.I., Ruda M.Ya. Development of the main directions in the treatment of patients with myocardial infarction in the last 25 years. Cardiology. 1989; 11: 11–5 (in Russ.).
  8. Shakhnovich R.M., Ruda M.Ya. The evolution of myocardial infarction treatment over the past decades. The significance of E.I. Chazov works. Therapeutic Archive. 2019; 91 (6): 25–33 (in Russ.). DOI: 10.26442/00403660.2019.06.000291
  9. Rentrop K.P., Feit F., Blanke H., Stecy P., Schneider R., Reyet M. et al. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. N. Engl. J. Med. 1984; 311: 1457–63. DOI: 10.1056/NEJM198412063112301
  10. Gruppo Italiano per lo Studio. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Lancet (London, England) 1986; 1: 397–402.
  11. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet (London, England). 1988; 2: 349–60.
  12. Gray D. Thrombolysis: past, present, and future. Postgrad. Med. J. 2006; 82: 372–5. DOI: 10.1136/pgmj.2005.033266
  13. Cannon C.P., McCabe C.H., Diver D.J., Herson S., Greene R.M., Shah P.K. et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J. Am. Coll. Cardiol. 1994; 24: 1602–10. DOI: 10.1016/0735-1097(94)90163-5
  14. Sgarbossa E.B., Pinski S.L., Barbagelata A., Underwood D.A., Gates K.B., Topol E.J. et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N. Engl. J. Med. 1996; 334: 481–7. DOI: 10.1056/NEJM199602223340801
  15. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 1993; 329: 673–82. DOI: 10.1056/NEJM199309023291001
  16. Hellstrom H.R. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 1991; 84: 1454–5. DOI: 10.1161/01.cir.84.3.1454
  17. Grüntzig A.R., Senning Å., Siegenthaler W.E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 1979; 301: 61–8. DOI: 10.1056/NEJM197907123010201
  18. O’Neill W., Timmis G.C., Bourdillon P.D., Lai P., Ganghadarhan V., Walton J., Jr. et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N. Engl. J. Med. 1986; 314: 812– 8. DOI: 10.1056/NEJM198603273141303
  19. Topol E.J., Califf R.M., George B.S., Kereiakes D.J., Abbottsmith C.W., Candela R.J. et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N. Engl. J. Med. 1987; 317: 581–8. DOI: 10.1056/NEJM198709033171001
  20. O’Keefe J.H., Rutherford B.D., McConahay D.R., Ligon R.W., Johnson W.L., Jr., Giorgi L.V. et al. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. Am. J. Cardiol. 1989; 64: 1221– 30. DOI: 10.1016/0002-9149(89)90558-4
  21. Grines C.L., Browne K.F., Marco J., Rothbaum D., Stone G.W., O’Keefe J. et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N. Engl. J. Med. 1993; 328: 673–9. DOI: 10.1056/NEJM199303113281001
  22. Nunn C.M., O’Neill W.W., Rothbaum D., Stone G.W., O’Keefe J., Overlie P. et al. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J. Am. Coll. Cardiol. 1999; 33: 640–6. DOI: 10.1016/s0735-1097(98)00622-6
  23. Tomberli B., Mattesini A., Baldereschi G.I., Mario C.D. A Brief history of coronary artery stents. Rev. Esp. Cardiol. 2018; 71: 312–9. DOI: 10.1016/j.rec.2017.11.022
  24. Schatz R.A., Baim D.S., Leon M., Ellis S.G., Goldberg S., Hirshfeld J.W. et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation. 1991; 83: 148–61. DOI: 10.1161/01.cir.83.1.148
  25. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I. et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 1994; 331: 496–501. DOI: 10.1056/NEJM199408253310802
  26. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G. et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 1994; 331: 489–95. DOI: 10.1056/NEJM199408253310801
  27. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N. Engl. J. Med. 1997; 336: 1621–8. DOI: 10.1056/NEJM199706053362301
  28. Stone G.W., Grines C.L., Cox D.A., Garcia E., Tcheng J.E., Griffin J.J. et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 2002; 346: 957–66. DOI: 10.1056/NEJMoa013404
  29. Bangalore S., Kumar S., Fusaro M., Amoroso N., Attubato M.J., Feit F. et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012 125: 2873–91. DOI: 10.1161/CIRCULATIONAHA.112.097014
  30. Mauri L., Silbaugh T.S., Garg P., E Wolf R., Zelevinsky K., Lovett A. et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N. Engl. J. Med. 2008; 359: 1330–42. DOI: 10.1056/NEJMoa0801485
  31. Stone G.W., Lansky A.J., Pocock S.J., J Gersh B., Dangas G., Wong S.C. et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N. Engl. J. Med. 2009; 360: 1946–59. DOI: 10.1056/NEJMoa0810116
  32. Mehran R., Brodie B., Cox D.A., Grines C.L., Rutherford B., Bhatt D.L. et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am. Heart J. 2008; 156: 44–56. DOI: 10.1016/j.ahj.2008.02.008
  33. Palmerini T., Benedetto U., Biondi-Zoccai G., Della Riva D., Bacchi-Reggiani L., Smits P.C. et al. Long-Term safety of drugeluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J. Am. Coll. Cardiol. 2015; 65: 2496– 507. DOI: 10.1016/j.jacc.2015.04.017
  34. Räber L., Magro M., Stefanini G.G., Kalesan B., van Domburg R.T., Onuma Y. et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012; 125: 1110–21. DOI: 10.1161/CIRCULATIONAHA.111.058560
  35. Gutiérrez-Chico J.L., Jüni P., García-García H.M., Regar E., Nüesch E., Borgia F. et al. Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with optical coherence tomography until complete resorption of the polymer. Am. Heart J. 2011; 162: 922–31. DOI: 10.1016/j.ahj.2011.09.005
  36. Ali Z.A., Gao R., Kimura T., Onuma Y., Kereiakes D.J., Ellis S.G. et al. Three-year outcomes with the absorb bioresorbable scaffold. Circulation. 2018; 137: 464–79. DOI: 10.1161/CIRCULATIONAHA.117.031843
  37. Reimer K.A., Vande Heide R.S., Richard V.J. Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models. Am. J. Cardiol. 1993; 72 (19): G13–21. DOI: 10.1016/0002-9149(93)90102-i
  38. Чазов Е.И. (ред.) Инфаркт миокарда. Монография. М.; Медицина: 1971. Chazov E.I. (Ed.) Myocardial Infarction: Monograph. Moscow; 1971 (in Russ.).
  39. Reimer K.A., Lowe J.E., Rasmussen M.M., Jennings R.B. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977; 56: 786–94. DOI: 10.1161/01.cir.56.5.786
  40. Boersma E., Maas A.C., Deckers J.W., Simoons L. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet (London, England). 1996; 348: 771–5. DOI: 10.1016/S0140-6736(96)02514-7
  41. Goldberg R.J., Mooradd M., Gurwitz J.H., Rogers W.J., French W.J., Barron H.V. et al. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). Am. J. Cardiol. 1998; 82: 259–64. DOI: 10.1016/s0002-9149(98)00342-7
  42. Vorontsova S.A., Pavlova T.V., Khokhlunov S.M., Podlipaeva A.A. Optimal management of patients with STsegment elevation myocardial infarction with delayed admission to the percutaneous coronary intervention center (more than 12 hours). Russian Journal of Cardiology. 2021; 26 (3S): 4518 (in Russ.). DOI: 10.15829/1560-4071-2021-4518
  43. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020; 25: 4103 (in Russ.). DOI: 10.15829/1560-4071-2020-4103
  44. Shpektor A.V., Vasilieva E.Yu. ST-elevation myocardial infarction: from “acute myocardial infarction network” to shockcenters. Creative Cardiology. 2021; 15 (4): 435–9 (in Russ.). DOI: 10.24022/1997-3187-2021- 15-4-435-439
  45. Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa F., Jeppsson A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur. J. Cardiothorac. Surg. 2018; 53: 34–78. DOI: 10.1093/ejcts/ezx334
  46. Mackman N., Spronk H., Stouffer G.A., Cate H.T. Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. Arterioscler. Thromb. Vasc. Biol. 2018; 38: 726–32. DOI: 10.1161/ATVBAHA.117.310048
  47. Costa F., Valgimigli M. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 2015; 373: 1271–2. DOI: 10.1056/NEJMc1508692
  48. Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 2007; 49: 1982–8. DOI: 10.1016/j.jacc.2007.03.025
  49. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb Sh. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2007; 357: 2001–15. DOI: 10.1056/NEJMoa0706482
  50. Palasubramaniam J., Wang X., Peter K. Myocardial Infarctionfrom atherosclerosis to thrombosis. Arterioscler. Thromb. Vasc. Biol. 2019; 39: E176–85. DOI: 10.1161/ATVBAHA.119.312578
  51. Féliste R., Delebassée D., Simon M.F., Chap H., Defreyn G., Vallée E. et al. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res. 1987; 48: 403–15. DOI: 10.1016/0049-3848(87)90398-7
  52. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000; 102: 624–9. DOI: 10.1161/01. cir.102.6.624
  53. Murphy S.A., Antman E.M., Wiviott S.D., Weerakkody G., Morocutti G., Huber K. et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITONTIMI 38 trial. Eur. Heart J. 2008; 29: 2473–9. DOI: 10.1093/eurheartj/ehn362
  54. O’Gara P.T., Kushner F.G., Ascheim D.D., Casey, D.E., Jr., Chung M.K., Lemos J.A. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127. DOI: 10.1161/CIR.0b013e3182742cf6
  55. Ibanez B., James S., Agewall S., Antunes M.J., BucciarelliDucci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018; 39 (2): 119–77. DOI: 10.1093/eurheartj/ehx393. PMID: 28886621
  56. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009; 361: 1045–57. DOI: 10.1056/NEJMoa0904327
  57. Steinhubl S.R., Berger P.B., Mann J.T., Fry E.T.A., DeLago A., Wilmer C. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411–20. DOI: 10.1001/jama.288.19.2411
  58. Mauri L., Kereiakes D.J., Yeh R.W., Driscoll-Shempp P., Cutlip D.E., Gabriel Steg P. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med. 2014; 371: 2155–66. DOI: 10.1056/NEJMoa1409312
  59. Yeh R.W., Kereiakes D.J., Steg P.G, Driscoll-Shempp P., Cutlip D.E., Gabriel Steg P. et al. Benefits and risks of extended duration dual antiplatelet therapy after pci in patients with and without acute myocardial infarction. J. Am. Coll. Cardiol. 2015; 65: 2211–21. DOI: 10.1056/NEJMoa1409312
  60. Bonaca M.P., Bhatt D.L., Cohen M., Steg P.G., Storey R.F., Jensen E.C. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 2015; 372: 1791– 800. DOI: 10.1056/NEJMoa1500857
  61. Bonaca M.P., Im K., Magnani G., Bansilal S., Dellborg M., Storey R.F. et al. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI Eur. Heart J. 2022; 43: 5037–44. DOI: 10.1093/eurheartj/ehac402

About Authors

  • Anastasiya S. Efendieva, Postgraduate, Junior Researcher; ORCID
  • Naida I. Bulaeva, Cand. Biol. Sci., Senior Researcher, Associated Professor, Cardiologist, Head of Department; ORCID
  • Elena Z. Golukhova, Dr. Med. Sci., Professor, Academician of RAS, Director; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery